Background: A large number of SCN5A variants have been reported to underlie
| INTRODUCTION
Brugada syndrome (BrS) is a genetic arrhythmia syndrome characterized by spontaneous or drug-induced J point elevation in the right precordial electrocardiogram (ECG) leads and is associated with a risk of malignant ventricular arrhythmias and sudden cardiac death (SCD).
Over the past two decades, significant progress has been made in elucidating the genetic basis of BrS. According to current estimates, causative mutations have been identified in a third of patients with BrS, [1] [2] [3] the vast majority of which have been identified in the SCN5A
gene. 4 On the basis of recent evidence, of the 21 genes implicated in BrS, only SCN5A has definitive evidence linking it to a BrS phenotype. 5 Interpretation of genetic data in patients with BrS remains complex. With the emergence of more refined strategies for variant classification and rapidly emerging data on genetic variation in normal populations, periodic re-evaluation of genetic variants underlying BrS is an important consideration. Re-evaluation of genetic variants in SCN5A is particularly relevant as the gene has a high background rate of rare variation. 6, 7 Furthermore, there is a high degree of variation in the strategies used for analysis of previously reported BrS variants.
In the current study, we re-assessed the pathogenicity of all the SCN5A variants previously reported in BrS using a modified version of the 2015 American college of medical genetics and genomics and the association for molecular pathology (ACMG-AMP) guidelines. 8 We used a standardized approach for variant assessment using the gnomAD population database and in silico variant prediction tools.
| METHODS

| Systematic literature search
A PubMed/Embase search was performed on January 12, 2017 using the search terms "Brugada." Based on the association between SCN5A
variants and other overlapping phenotypes (conduction abnormalities, short-QT syndrome, long-QT syndrome [LQTS] ), additional searches were performed using the terms "SCN5A mutation" or "SCN5A variant."
Abstracts for all identified manuscripts were reviewed. All studies that included cases/cohorts of BrS patients and all studies involving functional analysis of genetic variants were reviewed in full. Only English language articles in the following categories were included in final analysis;
(1) original studies/case reports identifying genetic variants, (2) studies investigating the functional significance of genetic variants, and (3) compendia of genetic variants underlying BrS.
Where available, ECGs from original manuscripts were reviewed and a diagnosis of BrS reconfirmed by two independent investigators.
The diagnosis of BrS was based on current consensus guidelines. 9 
| Analysis of pathogenicity
The strategy for variant analysis was based on the 2015 ACMG-AMP guidelines. A detailed breakdown of the scoring system is included in Tables 1 and 2 . Of the 27 ACMG-AMP rules, 13 were deemed not to be applicable. Details on the rationale for excluding these criteria are included in the Supporting Information text.
| Analysis of segregation
Criteria for variant segregation (PP1) included: (1) presence in greater than two family members with BrS within the same pedigree or (2) presence in one family members with BrS and one or more family member with a related phenotype (conduction abnormality, short-QT syndrome, LQTS-in the same pedigree with a complex overlapping phenotype) or (3) reported in an isolated BrS case but also reported in a separate pedigree (two or more family members)
with BrS-related phenotypes (in the absence of BrS in that pedigree).
Evidence from segregation analysis was upgraded from "supporting"
to "moderate" in the presence of linkage data with a logarithm of the odds (LOD) score of greater than 3. The presence of affected noncarriers was considered as strong evidence of benign status (BS4). The ACMG-AMP recommendation for demonstration of segregation in more than one family was waived as SCN5A is an established BrS gene.
| Analysis of functional data
Cellular electrophysiology studies demonstrating a loss-of-function effect were considered as strong evidence (PS3). Functional evidence was considered insufficient for PS3 if cellular electrophysiology studies demonstrated a less than 50% reduction in peak I Na without significant gating abnormalities predicted to decrease current under physiological conditions. Functional data were also excluded in the presence of conflicting evidence between studies. Functional studies demonstrating no effect on peak I Na (in the absence of gating abnormalities) were considered as supportive evidence of benign status (BS3). http://gnomad.broadinstitute.org/). Variant frequency was classified as "ultra rare," "rare" and "common" using a similar strategy as that of a recent report by Clemens et al. 10 The prevalence of BrS due to SCN5A variants is predicted to be 1/10 000 (BrS prevalence 1/2000 with estimated prevalence of SCN5A variants in BrS of 1/5).
| Analysis of variant frequency
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Therefore,~12 individuals in gnomAD would be predicted to have 
| Variant enrichment in BrS cases
The gnomAD population was used as a proxy for healthy controls.
Only "ultra-rare" variants in BrS cohorts (absent from global gnomAD cohort) were considered for enrichment analysis. To minimize the risk of duplicate counting (due to authorship overlap and interlaboratory collaborations), for those variants that were reported by the same authors in multiple studies, only the study reporting the maximum number of variants was considered. The presence of the variant in more than five BrS cases was considered as strong evidence (PS4).
| Computational evidence
In silico analysis was performed with five protein-level prediction tools: SIFT, 15 PolyPhen, 16 Mutation Taster, 17 Mutation assessor, 18 FATHMM, 19 and three conservation metrics: GERP++, 20 PhyloP conservation 21 and SiPhy 22 (thresholds for conservation for GERP++, PhyloP, and SiPhy were 4.4, 1.6, and 12.17, respectively). 23 A predicted pathogenic effect with more than six in silico tools was considered as supporting evidence (PP3) while less than two tools was considered as supporting evidence of benign status (BP4).
| Location in critical functional domain
The universal protein resource (www.uniprot.org) was used to classify variant location within the major SCN5A topology regions: 4 Null variants were not scored according to this criterion.
| Statistical analyses
Analysis of the relative contribution of each score component to the final variant classification was performed using a multiple logistic regression (SigmaPlot v11.0, Systat Software Inc, San Jose, CA). Each score component was included as an independent variable. Regression coefficients were calculated as the natural logarithm of odds ratios. Statistical significance was taken as P < 0.05 and if the 95% confidence intervals for regression coefficients did not cross 0.
3 | RESULTS
| Identification of studies
A flow chart demonstrating the criteria for study selection is included in Figure 1 . 
| Summary of variants
In all, 536 unique SCN5A variants were identified to underlie BrS and/or conduction disease. In the current study, we focused only on variants that resulted in a BrS phenotype in at least one variant carrier (480 SCN5A variants fulfilled this criterion). SCN5A variants that have been reported to result in conduction abnormalities only (in the absence of a BrS phenotype) were not analyzed using the ACMG-AMP guidelines (a list of these variants is included in Supporting Information Three hundred and one of 425 (71%) coding variants were classified as "ultra rare" (absent from global gnomAD population).
When analyzing variant frequency in the global gnomAD database (~123 000 exomes), 62 (14.5%) variants were classified as "rare"
(present in one to four individuals) and 62 (14.5%) were classified as "common" (present in more than five individuals). Based on the ethnicity-adjusted analysis, 52 of 425 (12%) were classified as rare, and 72 of 425 (17%) were classified as common (Supporting Information Table 5 ). Overall therefore, 10 of 425 (2%) variants were reclassified based on ethnicity-specific analysis. Nine of 425 (2%) variants were not only absent in the global gnomAD population but were also statistically overrepresented in BrS cases.
Of the 303 analyzed SCN5A variants, 243 (80%) had a predicted pathogenic effect with more than six in silico tools, and 26 (9%) had a predicted pathogenic effect with less than two in silico tools (Supporting Information Table 6 ).
| ACMG-AMP variant scoring
Overall, based on a modified version of the ACMG-AMP guidelines, only 37% of SCN5A variants fulfilled the criteria for a pathogenic or likely Figure 2 and Supporting Information Table 7 .
Based on multiple logistic regression analysis, the strongest score drivers for a pathogenic/likely pathogenic classification were: "null C-terminus, n = 5; interdomain linker, n = 4; N-terminus, n = 3).
Interestingly, all 11 variants deemed benign or likely benign localized to intracytoplasmic regions of the protein (N-terminus, n = 2;
C-terminus, n = 3; cytoplasmic regions of transmembrane-spanning domains, n = 6).
| Comparison with an SCN5A-specific scoring system
We compared the our ACMG-AMP classifications of missense variants to those derived from an classification system designed by Kapplinger et al, 26 which is largely based on analysis of protein topology and in silico prediction. Of the 171 unique variants reported in the Kapplinger study, only 95 (56%) had consistent classifications with our ACMG-AMP classifications (Supporting Information Table 7 ). The majority (82%) of the inconsistent classifications involved a downgrade from a "probably pathogenic" classification with the Kapplinger system to a "VUS" classification with the ACMG-AMP classification.
| DISCUSSION
In the current study, we demonstrate that based on contemporary ACMG-AMP guidelines, only 37% of SCN5A variants previously In the current study, we addressed some of the sources of heterogeneity by applying standardized in silico analysis and analysis of variant frequency. However, the absence of functional and segregation data for a large number of studies remains an important confounding factor. This limitation is particularly relevant when considering the fact that functional evidence was the major score driver for pathogenicity/likely pathogenicity for missense variants.
It is important to emphasize that the ACMG-AMP guidelines are primarily designed for analysis of monogenic traits and increasing evidence is emerging to suggest that BrS is an oligogenic disorder with complex association. In addition to studies reporting compound mutations in BrS patients, genome-wide association studies have reported that common variants influence susceptibility to BrS. [27] [28] [29] Furthermore, pedigree-based studies have reported a low disease penetrance among SCN5A variant carriers. 30 Indeed, in a study involving large BrS pedigrees, Probst et al 31 
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The ACMG-AMP framework is designed for universal applicability and the use of the criteria for BrS is associated with important potential limitations. More specifically, the lack of granularity for a number of guidelines is an important contributor to variations in classification. 32 This point is underscored by the differences in approach to variant classification between the current study and a recent report by Kroncke et al. 33 They used a subset of ACMG-AMP criteria to analyze the pathogenicity of SCN5A variants. While their study involved a combination of BrS and LQTS (with two-thirds of variants associated with BrS), as compared to the current study, a higher proportion of SCN5A variants (47%) fulfilled the criteria for likely pathogenicity. There are a number of differences in their approach that may account for the differences in classification. First, they applied four of the ACMG-AMP criteria in their study, while we applied 14 criteria.
Second, they deemed all missense SCN5A as fulfilling criterion PP2
(missense variant in a gene with a low rate of benign missense variation and missense variants are a common mechanism of disease). On the basis of a reported background SCN5A variation rate of between 2% and 5%, we deemed this criterion not to be applicable. 4, 7, 14, 34 Third, their criterion for enrichment (PS4; prevalence of variant in affected individuals significantly increased compared with controls) was set to greater than 20% of carriers presenting with either BrS or LQT3. In the current study, we set a specific enrichment threshold which we believe aligns more closely with ACMG-AMP recommendations. Finally, while their study involved two bioinformatics tools, our study involved five. 31 Kapplinger et al 26 recently developed an enhanced scoring system for SCN5A variants underlying BrS. Interestingly, we | 125 demonstrated a relatively high degree of inconsistency between our ACMG-AMP guideline-based approach and scores generated using the aforementioned enhanced scoring system. ACMG-AMP guideline-based scoring "downgraded" close to a third of variants to a VUS status. There are a number of explanations for the differences between the scoring systems. First, while the Kapplinger scoring is largely driven by protein topology and in silico prediction, the ACMG-AMP guidelines are less weighted towards these criteria. Second, the ACMG-AMP guidelines are more stringent in terms of the number of criteria necessary for pathogenic classification. Third, the ACMG-AMP classifications are based on more diverse criteria. These inconsistencies underscore the point that because the ACMG-AMP guidelines are designed for general applicability, some rules are potentially overly conservative. 25, 32 As discussed above, the presence of functional data is a major score driver for missense variants. However, analysis of functional data for 
| Limitations
There are a number of potential limitations associated with our analysis. First, variant interpretation is subject to inherent interlaboratory variation in interpretation. 39 In the current study, we did not test for inter-or intra-laboratory reproducibility of variant classification. Second, phenotypic data, and in particular ECG data, were only available for a quarter of the variants. The strength of the phenotypic data plays an important role in the interpretation of genotypic findings. Finally, there are multiple loss-of-function SCN5A
variants that lead to phenotypes other than BrS. While we have included a list of these variants, scoring was restricted to variants where at least one carrier presented with BrS. 
| Conclusions
